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Abstract
Objective: To assess the importance, for vasoconstriction, of in situ angiotensin (Ang) II generation, as opposed to Ang II delivery to
AT receptors via the organ bath fluid. Methods: Ang I and II concentration–response curves in human and porcine coronary arteries
(HCAs, PCAs) were constructed in relation to estimates of the clearances of Ang I and II (Cl , Cl ) from the organ bath and theAngI AngII
release of newly formed Ang II (R ) into the bath fluid. HCAs were from 25 heart valve donors (age 5–54 years), and PCAs from 14AngII
pigs (age 3 months). Results: Ang I- and II-evoked constrictions were inhibited by the AT receptor antagonist, irbesartan, and were not1
influenced by the AT receptor antagonist, PD123319. In HCAs Ang II was only three times more potent than Ang I, whereas, in the2
experiments with Ang I, comparison of Cl with Cl and R indicated that most of the arterially produced Ang II did not reachAngI AngII AngII
the bath fluid. Also in PCAs Ang I and II showed similar potency. In HCAs both the ACE inhibitor, captopril, and the chymase inhibitor,
chymostatin, inhibited Ang I-evoked vasoconstriction, while only chymostatin had a significant effect on Cl . In PCAs Ang I-evokedAngI
vasoconstriction was almost completely ACE-dependent. Conclusions: This study points towards the functional importance of in situ
ACE- and chymase-dependent Ang II generation, as opposed to Ang II delivery via the circulation. It also indicates that functionally
relevant changes in local Ang I–II conversion are not necessarily reflected by detectable changes in circulating Ang II. Ó 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction to the AT receptors, as a result of local conversion of1
arterially delivered Ang I.
Since the classical experiments of Ng and Vane [1], it is The enzyme responsible for Ang I–II conversion, ACE,
known that the vasoconstrictor response to i.v. administra- is well characterized, but recently a serine protease,
tion of angiotensin (Ang) I is mainly caused by its chymase, has been described that also converts Ang I to
conversion in the pulmonary vascular bed. It is now Ang II [4–9]. This enzyme is present in many tissues,
established, however, that endogenous circulating Ang I is including heart and blood vessels but, unlike ACE, not in
converted to Ang II not only in the lungs but also in other blood plasma [4]. Chymase-like immunoreactivity has
vascular beds [2,3]. It is therefore possible that, under been demonstrated in the cardiac interstitium, and cardiac
natural circumstances, Ang II-dependent vasoconstriction mast cells and endothelial cells are sites of chymase
is stimulated not so much by arterially delivered circulat- biosynthesis and storage [6]. Interstitial fluid contains an
ing Ang II as by Ang II that is formed in close proximity endogenous inhibitor of chymase, a -antitrypsin [9].1
The physiological importance of chymase is presently
unknown and may differ between species [8]. Most studies
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investigating this enzyme have determined its activity in 2.2. Collection of coronary arteries and tissue
tissue homogenates [4–9]. In vivo evidence supporting its preparation
role in Ang I–II conversion is still lacking but chymase
has been implicated in the return of plasma Ang II to its HCAs were obtained from 25 ‘heart beating’ organ
normal level, after its initial suppression, in humans and donors (13 male, 12 female; age 5–54 years, mean6SEM
animals on continuous ACE inhibitor treatment. Both in 3763 years) who died of non-cardiac causes (fourteen
humans and pigs, however, ACE inhibitor treatment cerebrovascular accident, seven head trauma, four hypoxia)
caused more than 90% inhibition of Ang I–II conversion less than 24 h before the heart was taken to the laboratory.
in the coronary vascular bed [3,10]. Moreover Ang I–II Hearts were provided by the Rotterdam Heart Valve Bank
conversion in freshly-obtained intact porcine coronary and (Bio Implant Services /Eurotransplant Foundation) after
carotid arteries appeared to be due to ACE only [11]. In removal of the aortic and pulmonary valves for trans-
contrast, the contractile response to Ang I in intact human plantation purposes. The study was approved by the joint
coronary arteries, obtained from hearts that had been kept Ethics Committee of the Erasmus University and the
for 2–10 h in ice-cooled Krebs–Henseleit solution, was University Hospital, Rotterdam. Immediately after circulat-
inhibited by the chymase inhibitor chymostatin and not by ory arrest, the hearts were stored in an ice-cooled sterile
the ACE inhibitor cilazaprilat [7]. In the latter study only organ-protecting solution (University of Wisconsin,
one (high) concentration of Ang I (1.0 mmol / l) was tested, EuroCollins, HTK Bretschneider, or St. Thomas Hospital).
and the possiblity of a cilazaprilat-induced shift in the Ang After arrival in the laboratory, the HCA was removed and
I concentration–response curve (CRC) was not investi- stored overnight in a cold, oxygenated Krebs bicarbonate
gated. It is also unknown to what degree mast cells are solution of the following composition (mmol / l): NaCl 118,
disrupted by the preparation of cardiac tissue and by its KCl 4.7, CaCl 2.5, MgSO 1.2, KH PO 1.2, NaHCO2 4 2 4 3
storage in organ-protecting solution. 25, and glucose 8.3; pH 7.4. Vessels were then cut into
In the experiments reported here we address these issues segments of approximately 4-mm length (wet weight 25–
by constructing Ang I and Ang II CRCs in human 50 mg), suspended on stainless steel hooks in 15-ml organ
coronary arteries (HCAs) and porcine coronary arteries baths containing Krebs bicarbonate solution, aerated with
(PCAs), in the presence and absence of inhibitors of ACE 95% O –5% CO , and maintained at 378C. Segments2 2
and chymase. Ang II is a well-known vasoconstrictor of containing macroscopically visible atherosclerotic lesions
coronary arteries in vivo [12,13]. We studied the angioten- were not used.
sin-induced responses in relation to measurements of Ang I PCAs were obtained from 14 female 3-month-old pigs
and Ang II in the organ bath fluid, in order to assess the (Yorkshire3Landrace, weight 10–15 kg). The pigs had
importance, for vasoconstriction, of in situ Ang II genera- been used in in vivo studies of the hemodynamic effects of
tion, as opposed to Ang II delivery to the vascular a-adrenoceptor and serotonin receptor agonists and antago-
receptors via the organ bath. HCAs were obtained from nists under pentobarbital (600 mg, i.v.) anesthesia [14].
organ donor hearts that had been kept in an organ-protect- The protocol for this investigation had been approved by
ing solution. PCAs were obtained both from freshly the Ethics Committee of the Erasmus University, Rotter-
explanted hearts and from hearts that had been stored in an dam, dealing with the use of animals for scientific experi-
organ-protecting solution. ments. The heart was explanted at the end of the experi-
ment, and the PCA was either removed immediately (n57)
or after the heart had been stored for 24 h in an organ-
protecting solution (HTK Bretschneider, n54, or St.
2. Methods Thomas Hospital, n53). The storage was done to mimic
the situation for the human hearts. After their removal
2.1. Chemicals PCAs were handled in the same way as HCAs.
5 5[Ile ]-Angiotensin I (Ang I), [Ile ]-angiotensin II (Ang 2.3. Experimental protocol
II), a -antitrypsin, captopril, chymostatin, L-NAME, pros-1
taglandin F and substance P were purchased from Sigma. All vessel segments were allowed to equilibrate for at2a
The AT receptor antagonist irbesartan was a gift of least 30 min and the organ bath fluid was refreshed every1
Bristol-Myers Squibb. The AT receptor antagonist 15 min during this period. Changes in tissue contractile2
PD123319 was a gift of Parke Davis. All compounds were force were recorded with a Harvard isometric transducer.
dissolved in distilled water, with the exception of chymos- The vessel segments, stretched to a stable force of about 15
1tatin, which was dissolved in dimethylsulfoxide, and mN, were exposed to 30 mmol / l K twice. The functional
irbesartan, which was dissolved in ethanol. Stock solutions integrity of the endothelium was verified by observing
of chymostatin and irbesartan had concentrations of 10 and relaxation to 1 nmol / l substance P after pre-contraction
1 mmol / l, respectively. with 1 mmol / l prostaglandin F [15]. Expressed as a2a
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percentage of the prostaglandin F -mediated contraction, therefore virtually free of degrading enzymes. In a previ-2a
the relaxation induced by substance P was 5968% (n525) ous study of the metabolism of Ang I by PCAs, in which
125in HCAs and 100% or more in PCAs. Subsequently, the I-Ang I was added to the organ bath and its metabolites
1tissue was exposed to 100 mmol / l K to determine the were identified in the bath fluid by HPLC, the main peptide
1 125 125
maximal contractile response to K . The segments were peaks corresponded with intact I-Ang I and intact I-
125 125then allowed to equilibrate in fresh organ bath fluid for 30 Ang II with very little I-Ang-(2–10) and I-Ang-(4–
min. Thereafter, the vessel segments were pre-incubated 8) [11]. We therefore tested a simplified technique, i.e.
with or without 100 mmol / l captopril, 100 mmol / l radioimmunoassay without prior SepPak extraction and
chymostatin, 100 mmol / l captopril plus 100 mmol / l HPLC separation.
chymostatin, 1.0 mg/ml a -antitrypsin, 1 mmol / l irbesar- In two complete series of HCA experiments (i.e., control1
tan or 1 mmol / l PD123319. Pre-incubation of PCAs was experiments and experiments in the presence of captopril,
carried out in the presence of 100 mmol / l L-NAME. chymostatin, captopril plus chymostatin and a -an-1
L-NAME caused an increase in basal tone, which indicates titrypsin), all bath fluid samples taken at 15 and 60 min
a high basal level of nitric oxide generating activity in after the addition of 1.0 mmol / l Ang I were assayed after
these vessels. Without L-NAME, Ang I and Ang II were SepPak extraction and HPLC separation as well as without
unable to contract PCAs. In HCAs, Ang I- and Ang extraction and separation. The simplified Ang II assays
II-induced contractions were similar with and without showed good agreement with the assays after extraction
L-NAME (n53; data not shown), and these vessels were and HPLC separation (Fig. 1). The same was true for the
therefore not pre-incubated in the presence of L-NAME. Ang I assays (results not shown). Ang I and II con-
Following 30-min pre-incubation, Ang I and Ang II (0.1 centrations presented under Results are based on measure-
nmol / l–1.0 mmol / l) CRCs were constructed. It took 5–10 ments made using the simplified technique.
min to reach a stable contraction plateau, and subsequent
angiotensin doses were given rapidly after a stable plateau 2.5. Data analysis
had been reached, in order to minimise desensitisation. To
estimate the release of newly formed Ang II into the organ Data are given as mean6SEM and expressed as a
bath, bath fluid samples (50 ml) for Ang II measurements percentage of the contraction in response to 100 mmol / l
1
were taken at the time the Ang I CRCs were constructed, K (4163 mN in HCAs, n525; 3362 mN in PCAs,
15 min after the addition of 0.3 mmol / l Ang I and 15 min n514). CRCs were analyzed using the logistic function
10
after the addition of 1.0 mmol / l Ang I, i.e. at the time a described by de Lean et al. [18] to obtain pEC (2 log50
stable contraction had been reached. The elimination of EC ) values. In the presence of enzyme inhibitors, Ang I50
Ang I and II was estimated from their measurement in CRCs in HCAs did not always reach a maximum (E ) atmax
samples taken just after the addition of 1.0 mmol / l Ang I the highest Ang I concentration of 1.0 mmol / l. In such
and II, and 15, 30 and 60 min later. All samples were cases we determined the Ang I concentration required to
1
rapidly mixed with 5 ml angiotensinase inhibitor solution obtain 5% of the K -induced contraction (E ), in order15%K
and stored at 2808C [16]. to calculate the pEC value. E corresponded to1 15%K 5%K
|25% of the E in the absence of enzyme inhibitors. Themax
2.4. Measurement of angiotensin I and II addition of L-NAME caused an increase in basal tone in
PCAs. The responses to Ang I and Ang II were corrected
Ang I and II concentrations in the organ bath fluid of for this increase in baseline. Statistical analysis was by
HCAs were measured using sensitive radioimmunoassays one-way ANOVA, followed by post hoc evaluation (ac-
[17]. Measurements were made in samples diluted 1:100 or cording to Tukey or Dunnett where appropriate). P values
1:50 with 0.01 mol / l phosphate buffer, pH 7.4, containing ,0.05 were considered significant.
0.15 mol / l NaCl (total volume 100 ml). The Ang I
antiserum crossreacted (100%) with Ang-(2–10) but not
(,0.1%) with Ang II, Ang-(2–8), Ang-(3–8) and Ang-(4– 3. Results
8). The Ang II antiserum crossreacted with Ang-(2–8),
Ang-(3–8) and Ang-(4–8) (55%, 73% and 100%, respec- 3.1. Vasoconstrictor responses
tively) but virtually not (,0.2%) with Ang I and Ang-(2–
10). 3.1.1. Angiotensin I- vs. II-evoked responses
In blood plasma it is necessary to perform the radioim- In HCAs (Fig. 2, left panel) Ang I and II displayed
munoassays after SepPak extraction and high-performance similar maximal effects (E 1865% and 1763%, respec-max
liquid chromatography (HPLC) separation of the angioten- tively, n513). Ang I in HCAs was less potent than Ang II,
sins to remove interfering agents and crossreacting an- but the difference was small (pEC 7.360.1 and 7.860.1,50
giotensin peptides. The organ bath fluid is a buffered respectively, P,0.001). Also in PCAs Ang I and II
solution, and the assay samples are highly diluted and displayed the same maximal effect (E 6.962.1% andmax
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Fig. 1. Comparison between Ang II levels in organ bath fluid measured with and without prior HPLC separation. The line represents the line of identity.
5.462.0%, respectively, n514), and Ang I was as potent between PCAs from fresh hearts and PCAs from hearts
as Ang II (pEC 8.360.2 and 8.760.2, respectively, that had been stored for 24 h in an organ-protecting50
P5NS). There was no significant difference in response solution. Data of all PCAs were therefore combined (Fig.
Fig. 2. Left panel. Contractions of HCAs to Ang I (open circles), Ang II (open squares), Ang I in the presence of the AT receptor antagonist irbesartan (11
mmol / l; closed triangles), Ang II in the presence of irbesartan (1 mmol/ l; closed diamonds), Ang I in the presence of the AT receptor antagonist PD2
123319 (1 mmol/ l; closed circles), and Ang II in the presence of PD 123319 (1 mmol/ l; closed squares). Right panel. Contractions of HCAs to Ang I in the
absence (open circles) or presence of captopril (100 mmol / l; closed squares), chymostatin (100 mmol / l; closed circles), captopril plus chymostatin (both
100 mmol / l; 1symbols) or a -antitrypsin (1.0 mg/ml; closed triangles). Data are expressed as a percentage (mean6SEM; n56–13) of the response to 1001
1
mmol / l K .
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Fig. 3. Left panel. Contractions of PCAs to Ang I (open circles), Ang II (open squares), Ang II in the presence of the AT receptor antagonist irbesartan (11
mmol / l; closed diamonds), and Ang II in the presence of the AT receptor antagonist PD 123319 (1 mmol/ l; closed squares). Right panel. Contractions of2
PCAs to Ang I in the absence (open circles) or presence of captopril (100 mmol / l; closed squares), chymostatin (100 mmol/ l; closed circles), captopril plus
chymostatin (both 100 mmol / l; 1symbols) or a -antitrypsin (1.0 mg/ml; closed triangles). Data are expressed as a percentage (mean6SEM; n57 or 14)1
1
of the response to 100 mmol / l K .
3). Ang I and II were about one order of magnitude more related to the fact that the increase in baseline contractile
potent in PCAs than in HCAs. force caused by L-NAME was smaller in the presence of
chymostatin than in its absence (6.361.3% and
3.1.2. Effects of AT receptor antagonists 15.961.1%, respectively; P,0.05). An increase in
Both in HCAs (Fig. 2, left panel) and PCAs (Fig. 3, left baseline contractile force is known to augment the contrac-
panel), the AT receptor antagonist irbesartan abolished tile response [19].1
the contractile response to Ang II. Irbesartan also abolished
the contractile responses to Ang I in HCAs (Fig. 2, left 3.2. Angiotensin I and II levels
panel). The AT receptor antagonist PD123319 was with-2
out effect in HCAs and PCAs. Ang I and II were not detectable in HCA organ bath
fluid (n54) prior to the addition of Ang I. The Ang II
3.1.3. Effects of inhibitors of ACE and chymase level in the organ bath at the time a stable contraction had
In HCAs, captopril, chymostatin, and captopril plus
chymostatin reduced the contractions caused by Ang I
(Fig. 2, right panel). As compared with the control
pEC value (7.660.2, n510), the pEC values in1 15%K 5%K
the presence of the above inhibitors were significantly
reduced (6.960.2, P,0.01, n510; 6.760.2, P,0.01, n5
9; and 6.260.1, P,0.01, n56, respectively). In the
presence of a -antitrypsin, the Ang I-induced contractions1
were not reduced and the pEC value (7.460.3, n56)15%K
was not different from control. The enzyme inhibitors did
not affect the Ang II CRCs (n55, Fig. 4), indicating that
their effect on Ang I-evoked contractions was caused by
inhibition of Ang II generation and not by interference
with the vasoconstrictor effect of Ang II.
Captopril, with or without chymostatin, virtually
abolished the response to Ang I in PCAs from fresh hearts
as well as in PCAs from stored hearts (Fig. 3, right panel,
Fig. 4. Contractions of HCAs to Ang II in the absence (open squares) orand Table 1). Chymostatin alone or a -antitrypsin did not1 presence of captopril (100 mmol / l; closed squares), chymostatin (100
cause a shift of the Ang I CRC in these vessels. The
mmol / l; closed circles), or a -antitrypsin (1.0 mg/ml; closed triangles).1
maximal contraction reached with Ang I was lower (P, Data are expressed as a percentage (mean6SEM; n55) of the response to
10.01) in the presence of chymostatin, which is most likely 100 mmol / l K .
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Table 1




None a -Antitrypsin Captopril Chymostatin Captopril1chymostatin1
Fresh hearts 8.360.2 8.260.1 ,6.0 8.360.0 ,6.0
Stored hearts 8.460.3 8.760.2 ,6.0 8.960.3 ,6.0
a Data are mean6SEM of seven experiments. pEC values ,6.0 indicate that the contractions reached at the highest angiotensin concentration were50
below 50% of the maximum response that was observed without inhibitors or antagonists.
been obtained, 15 min after the addition of 0.3 mmol / l virtually constant during the 60 min observation period,
Ang I, was 2.461.1 nmol / l in the absence of enzyme both in the absence and presence of captopril, a -an-1
inhibitors, 3.360.8 nmol / l in the presence of captopril, titrypsin or chymostatin (results not shown). The net
and 3.860.9 nmol / l in the presence of a -antitrypsin. It vascular release of Ang II into the organ bath was almost1
was close to or below the detection limit (0.5 nmol / l) in completely blocked by chymostatin (Fig. 5, bottom panel).
the presence of chymostatin or chymostatin plus captopril. Thus, both the disappearance of Ang I from the organ bath
The Ang II levels, 15 min after the addition of 1.0 mmol / l and the vascular release of newly formed Ang II into the
Ang I, were 5.662.6 nmol / l in the absence of enzyme bath were largely determined by chymase-dependent Ang
inhibitors, 6.360.7 nmol / l in the presence of captopril, I–II conversion.
8.462.7 nmol / l in the presence of a -antitrypsin and close Fig. 6 compares the organ bath fluid levels of Ang II1
to the detection limit in the presence of chymostatin or that were required for vasoconstriction when the artery was
captopril plus chymostatin. exposed to exogenous Ang II (i.e., after the addition of
Captopril and a -antitrypsin did not alter the rate of Ang II) with the levels of endogenous Ang II (i.e., after1
disappearance of Ang I from the organ bath, whereas the addition of Ang I) that were associated with similar
chymostatin and captopril plus chymostatin almost com- contractile responses. It appears that, under control con-
pletely prevented the decrease in Ang I (Fig. 5, top panel). ditions as well as in the presence of inhibitors, the bath
Ang II, after it had been added to the organ bath, remained fluid levels of Ang II required for the same contractile
response were 1.5–2 orders of magnitude higher with
exogenous Ang II than with endogenous Ang II.
4. Discussion
This study addresses the functional significance of
vascular in situ Ang I–II conversion as opposed to Ang II
delivery via the circulation. We found that the difference in
vasoconstrictor action between equimolar doses of Ang I
and Ang II was small in HCAs. Similar results have been
reported by others [20,21]. In PCAs Ang I and Ang II were
equipotent, possibly because in this preparation the syn-
thesis of NO, an endogenous inhibitor of ACE [22], was
suppressed by L-NAME. Ang I and Ang II were more
potent in PCAs than in HCAs, which may be related to the
higher affinity of the porcine AT receptors for Ang II1
[23–26].
ACE inhibition by captopril attenuated the vasoconstric-
tor response to Ang I in HCAs and PCAs. It has been
reported that the ACE inhibitor, cilazaprilat, did not alterFig. 5. Net decrease in Ang I (top panel) and increase in Ang II (bottom
the response to 1.0 mmol / l Ang I in HCAs isolated frompanel) in organ bath fluid of HCAs after the addition of 1.0 mmol/ l Ang I
in the absence (open circles) or presence of captopril (100 mmol / l; closed patients undergoing heart transplantation [7]. We also did
squares), chymostatin (100 mmol/ l; closed circles), captopril plus not observe a clear inhibitory effect of captopril at this
chymostatin (both 100 mmol; 1symbols), or a -antitrypsin (1.0 mg/ml;1 high dose of Ang I. Only by constructing a complete CRC
closed triangles). Data are expressed as a percentage (mean6SEM, n54) did this effect become apparent.
of the Ang I levels (1.060.1, 1.260.2, 1.060.1, 0.860.1 and 1.160.2
Chymase is known to catalyze Ang I–II conversion inmmol / l, respectively) measured immediately after the addition of Ang I
(t50). vitro and has been detected in human and porcine cardiac





A. MaassenVanDenBrink et al. / Cardiovascular Research 44 (1999) 407 –415 413
Fig. 6. Contractile responses of HCAs versus organ bath fluid levels of Ang II, measured 15 min after the addition of Ang I (0.3 and 1.0 mmol/ l), in the
absence (open circles) or presence of captopril (100 mmol / l; closed squares), chymostatin (100 mmol / l; closed circles), captopril plus chymostatin (both
100 mmol;1symbols), or a -antitrypsin (1.0 mg/ml; closed triangles). For comparison, the contractile responses of these vessel segments after the addition1
1
of Ang II (open squares) are also given. Contractile responses are expressed as a percentage (mean6SEM; n54) of the response to 100 mmol / l K .
tissue homogenates [27]. Inhibition of this enzyme by release of newly formed Ang II were reduced by captopril
chymostatin attenuated Ang I-evoked contractions in to very low levels [11], and this is in accordance with the
HCAs but not in PCAs. It is conceivable that this important contribution of ACE to Ang I-evoked contrac-
difference in response between HCAs and PCAs was tions in PCAs, as opposed to the important role of chymase
caused by the release of chymase from disrupted mast cells in HCAs.
during storage of the human hearts in organ-protecting In our experiments, a -antitrypsin, which is an inhibitor1
solution. Chymostatin, however, was without effect, in of chymase, did not inhibit Ang I-evoked contractions, in
PCAs prepared from hearts that had been stored in organ- spite of the fact that we added this inhibitor in a con-
protecting solution in the same way as the human hearts, as centration (1.0 mg/ml) that is about twice the concen-
well as PCAs from fresh hearts. tration in interstitial fluid [9]. This concentration has been
The important contribution of chymase to Ang I-induced shown to cause complete inhibition of chymase in human
vasoconstriction in HCAs was also suggested by the cardiac tissue homogenates [9]. Possibly, a -antitrypsin is1
effects of chymostatin on the Ang I elimination from the less effective as an inhibitor of chymase in intact tissue
organ bath and the release of newly formed Ang II into the than in tissue homogenates [28].
bath. Both were reduced to nearly zero by chymostatin, In the present study of HCAs the level of newly formed
while captopril had little effect. Ang II in the organ bath 15 min after the addition of Ang I,
It is important to note that, in contrast with the bath fluid i.e. at the time the vasoconstrictor response had reached a
level of Ang I after the addition of Ang I, the level of Ang stable plateau, was ,1% of the level of Ang I. We
II remained nearly constant after the addition of Ang II. obtained comparable results in an earlier study of PCAs
Since it is known that Ang I can serve as a substrate for [11]. These findings contrast with the small difference in
enzymes that degrade Ang II, our findings indicate that the vasoconstrictor potency between Ang I and Ang II. It
observed disappearance of Ang I from the organ bath was appears therefore that vasoconstriction following Ang I
primarily caused by Ang I–II conversion and not by Ang I administration was caused by in situ generated Ang II that
degradation without prior conversion. activates the vascular AT receptors before it reaches the1
In PCAs both the Ang I disappearance rate and the surrounding bath fluid. Vascular Ang I–II conversion in
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[6] Urata H, Boehm KD, Philip A et al. Cellular localization andclose proximity to AT receptors is an efficient mechanism1
regional distribution of an angiotensin II- forming chymase in theto produce a high concentration of Ang II at the site of the
heart. J Clin Invest 1993;91:1269–1281.
receptors. A study of the local generation of Ang II and its [7] Wolny A, Clozel J-P, Rein J et al. Functional and biochemical
vasoconstrictor effect in perfused rat hindquarters, compar- analysis of angiotensin II-forming pathways in the human heart. Circ
ing the venous Ang II levels after infusion of renin with Res 1997;80:219–227.
[8] Balcells E, Meng QC, Johnson Jr. WH, Oparil S, Dell’Italia LJ.those after infusion of Ang II, also indicated higher local
Angiotensin II formation from ACE and chymase in human andAng II levels than reflected by the Ang II concentrations in
animal hearts: methods and species considerations. Am J Physiolthe effluent [29]. 1997;273:H1769–1774.
There is no agreement on whether or not the long-term [9] Kokkonen JO, Saarinen J, Kovanen PT. Regulation of local an-
blood pressure-lowering effect of ACE inhibitors in intact giotensin II formation in the human heart in the presence of
interstitial fluid. Inhibition of chymase by protease inhibitors ofhumans and animals is correlated with the effect of these
interstitial fluid and of angiotensin-converting enzyme by Ang-(1–9)drugs on the circulating level of Ang II. This lack of
formed by heart carboxypeptidase A-like activity. Circulation
agreement is caused, at least partly, by the methodological 1997;95:1455–1463.
difficulty in measuring low levels of Ang II in the presence [10] Zisman LS, Abraham WT, Meixell GE et al. Angiotensin II
of high levels of Ang I [30]. The assay has to be highly formation in the intact human heart. Predominance of the angioten-
sin-converting enzyme pathway. J Clin Invest 1995;96:1490–1498.specific and sensitive, but not only that, any ex vivo Ang
[11] Danser AHJ, Chowdury S, de Lannoy LM, van der Giessen WJ,I–II conversion during blood sampling needs to be pre-
Saxena PR, Schalekamp MADH. Conversion and degradation of
vented. On top of this, our findings point towards a more 125[ I] labelled angiotensin I in isolated perfused porcine coronaryfundamental problem, namely the possibility that physio- and carotid arteries. Cardiovasc Res 1995;29:789–795.
logically relevant changes in local Ang I–II conversion [12] Cockroft JR, Keogh BE, Webb DJ, Ritter JM, Taylor KM. Re-
sponses to angiotensin with and without angiotensin-convertingafter ACE inhibitor treatment is not reflected by detectable
enzyme inhibition in the canine left anterior descending coronarychanges in circulating Ang II. In the present experiments
artery. Am J Cardiol 1993;71:1498–1499.with HCAs and in earlier experiments with PCAs [11] only [13] van Kats JP, Sassen LMA, Danser AHJ et al. Assessment of the role
a small fraction of the Ang I that had been converted by of the renin–angiotensin system in cardiac contractility utilizing the
the arteries appeared as intact Ang II in the organ bath. renin inhibitor remikiren. Br J Pharmacol 1996;117:891–901.
In humans the circulating level of Ang I is, under [14] de Vries P,Villalon CM, Heiligers JP, Saxena PR. Characterization of
5-HT receptors mediating constriction of porcine carotid arterioven-normal circumstances, higher than the circulating level of
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